Phreesia Earnings Call Transcripts
Fiscal Year 2027
-
Q2 FY2027 saw 10% revenue growth year-over-year, strong profitability, and positive cash flow, enabling a $23M debt reduction. Product innovation and segment expansion, especially AccessOne and ProviderConnect, are driving growth, with FY2027 guidance reaffirmed.
-
Revenue grew 13% year-over-year to $130.9 million, driven by payment and network solutions, with net income reaching $3 million and Adjusted EBITDA margin at 23%. Fiscal 2027 guidance is unchanged, with continued focus on AccessOne integration, operational efficiency, and new product momentum.
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by stockholders. No questions were submitted, and a quorum was established. Final voting results will be filed with the SEC.
-
Fiscal 2026 saw record Adjusted EBITDA, free cash flow, and first-ever positive GAAP net income, driven by AccessOne and operational efficiency. FY27 revenue guidance was lowered due to pharma spending headwinds, but margin and cash flow outlooks remain strong.
-
Q3 delivered 13% revenue growth and record margins, with strong cash flow and positive net income. The AccessOne acquisition expands provider financing capabilities, while new HCP marketing initiatives and AI-driven solutions are set to drive future growth.
-
Q2 FY2026 saw 15% revenue growth, first-ever positive net income, and a $160M AccessOne acquisition to expand the addressable market by $6B. Adjusted EBITDA margin reached 19%, and new AI products are driving strong engagement and future growth.
-
Revenue rose 15% year-over-year to $115.9M, with adjusted EBITDA up 16.7% and strong cash flow. FY2026 guidance was raised for adjusted EBITDA, and a share repurchase plan was authorized. Product innovation and AI integration continue to drive growth.
Fiscal Year 2025
-
Q4 revenue grew 15% year-over-year to $109.7M, with adjusted EBITDA of $16.4M and strong cash flow. Fiscal 2026 guidance is maintained, with continued growth in clients and per-client revenue expected. AI and new product rollouts are driving operational leverage and market differentiation.
-
Q3 FY2025 saw 17% revenue growth and strong margin expansion, with positive cash flow and a raised FY2025 Adjusted EBITDA outlook. FY2026 guidance projects 13–15% revenue growth and over 129% Adjusted EBITDA growth, supported by disciplined expense management and expanding client base.
-
Q2 saw 19% revenue growth and the first-ever positive free cash flow, with strong operating metrics and raised EBITDA guidance. Network solutions and larger deal sizes are driving future growth, while retention remains high and investments in new products and partnerships continue.